|Bid||94.30 x 1100|
|Ask||94.87 x 1400|
|Day's range||93.25 - 94.85|
|52-week range||58.59 - 98.97|
|Beta (3Y monthly)||1.50|
|PE ratio (TTM)||12.95|
|Earnings date||23 Oct 2019 - 28 Oct 2019|
|Forward dividend & yield||N/A (N/A)|
|1y target est||97.00|
INREBIC provides new, once-daily oral option for patients affected by rare bone marrow cancer
Agios' (AGIO) wholly owned precision medicine Tibsovo is picking up sales since its approval and strong sequential growth delivered in Q2. Undue reliance on Celgene for royalties is a constant worry.
Epizyme (EPZM) aims at developing its lead pipeline candidate, tazemetostat, which is under FDA review with an action date of Jan 23, 2020.
Each of these healthcare companies takes a different approach to fighting cancer, but all have what it takes to be long-term winners in your portfolio.
Zacks Industry Outlook Highlights: Gilead Sciences, Regeneron Pharmaceuticals, Amgen, Vertex Pharmaceuticals and Alexion Pharmaceuticals
In the absence of an approved product in Editas' (EDIT) portfolio, pipeline development remains in focus on the second-quarter earnings call.
ImmunoGen (IMGN) reports narrower-than-expected loss in the second quarter and beats revenue estimates. The company provides updated guidance for 2019.
Agios (AGIO) incurs wider-than-expected loss in Q2 while revenues beat estimates. The company's newly approved leukemia drug Tibsovo sees a rise in sales sequentially.
Impressive second-quarter results by most biotech bigwigs are the key highlights of the week. Most companies also increase their annual guidance.
Celgene (CELG) beats on earnings and sales in second-quarter 2019. The company raises full-year revenue guidance on solid Pomalyst and Abraxane performances.
Celgene (CELG) delivered earnings and revenue surprises of 9.16% and 3.82%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
SUMMIT, N.J.-- -- Strong total revenue of $4.4 billion, increased 15% Y/Y driven by volume Company raises 2019 total revenue guidance; reaffirms 2020 outlook Fedratinib, ozanimod and luspatercept regulatory filings accepted year-to-date; liso-cel BLA submission on-track for Q4:19 Celgene Corporation reported second quarter 2019 total revenue of $4,400 million, a 15 percent increase compared to $3,814 ...